January 2023 - Page 3 of 4 - BioMedWire (BMW)

TuesdayJan 17, 2023 10:30 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where he discussed recent successful results from the preclinical in vivo study, additional pipeline plans for other NanoAb therapeutics, and the company’s derisked R&D strategy Mainland China is experiencing a fresh wave of COVID-19 infections sweeping…

FridayJan 13, 2023 10:53 am

Researchers Design a New Way to Kill Cancer Using Cancer Cells

Researchers at Brigham and Women’s Hospital may have found another way to treat cancer; the new approach involves transforming cancer cells into anti-cancer agents. The researchers developed the new therapy approach, which can train the immune system to prevent the disease from recurring while also eliminating primary tumors. Dr. Khalid Shah, the study’s corresponding author, stated that the group’s objective was to turn cancer cells into cancer vaccines and killers. He explained that the scientists repurposed cancer cells using gene engineering to design a therapy that eliminated tumor cells and stimulated the immune system to prevent cancer and destroy established…

FridayJan 13, 2023 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes The company has since expanded the device’s…

ThursdayJan 12, 2023 11:44 am

Study Finds Pharmacotyping Pediatric Leukemia Offers Blueprint to Better Precision Medicine

Researchers at St. Jude’s Children Research Hospital have conducted a new study looking into drug sensitivity among patients with acute lymphoblastic leukemia across a variety of genetic subtypes. Acute lymphoblastic leukemia is a common childhood cancer that affects white blood cells. It is estimated that roughly 98% of children suffering from this cancer type will experience remission after a few weeks of treatment. Of this number, almost 90% will be cured. Current treatments for acute lymphoblastic leukemia are risk adapted, which means that chemotherapy is based on leukemia genomics, clinical features and the extent of minimal residual disease. The researchers’…

ThursdayJan 12, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization…

WednesdayJan 11, 2023 10:25 am

New Study Challenges Existing Theories about Alzheimer’s Disease

Alzheimer’s is a debilitating mental illness that affects more than 6 million Americans of all ages. The condition is especially prevalent among the elderly, with an estimated 6.5 million Americans aged 65 and older living with Alzheimer’s last year. Some figures show that 73% of the people living with Alzheimer’s are 75 years old and older. Alzheimer’s usually occurs when amyloid proteins build up abnormally in and around brain cells and form deposits of plaque, causing a reduction in neurotransmitter activity. The plaque buildup causes parts of the brain to shrink over time, usually beginning with the regions in charge…

TuesdayJan 10, 2023 12:42 pm

Scientific Review Highlights Stigma Directed at People Living with Chronic Pain

The International Association for the Study of Pain estimates that 20% of people worldwide live with chronic pain, with low- and middle-income countries reporting a higher chronic pain prevalence of around 33%. A recent scientific review by researchers from the Sapienza University of Rome has now revealed that chronic pain sufferers are increasingly becoming victims of stigma. Stigma is defined by the World Health Organization (WHO) as a mark of disgrace, shame or disapproval that results in discrimination and exclusion from the community. When patients suffer from stigmatized conditions such as HIV/AIDS, obesity, and chronic pain, they are much less…

TuesdayJan 10, 2023 12:00 pm

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100, seeking approval for Adimune(TM) to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023 ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune…

TuesdayJan 10, 2023 10:30 am

MetAlert, Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space

MetAlert is a pioneer in location-sensitive health monitoring devices and wearable technology products targeting the Alzheimer’s, Dementia, and Autism (“ADA”) market The company is looking to provide cutting-edge telehealth technologies and is continuously working to roll out improved and more innovative products for its users Its SmartSole(R) product facilitates discreet tracking and remote monitoring of ADA patients The company has also launched SmartSole plus(R), which adds Bluetooth and Wi-Fi capabilities for better tracking MetAlert also distributes RoomMate, a wall-mounted 3D infrared supervision product that enables caregivers to look after patients without intruding on their personal space The policy changes spearheaded…

MondayJan 09, 2023 10:43 am

America Faces Shortage of Infectious Disease Experts

The United States is currently facing a critical shortage of infectious disease experts. Infectious disease doctors, or IDs as they are commonly referred to in hospitals, are usually tasked with diagnosing diseases and guiding hospital teams in treatment. This tends to involve collecting extensive and detailed medical histories and reviewing past medical records thoroughly to identify the root cause of a patient’s symptoms. Unsurprisingly, this infectious disease expert work requires a tremendous amount of cognitive effort and plays a critical role in the proper diagnosis and treatment of patients. It also requires key qualifications, with ID doctors having to go…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: January 2023

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

Researchers Design a New Way to Kill Cancer Using Cancer Cells

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

Study Finds Pharmacotyping Pediatric Leukemia Offers Blueprint to Better Precision Medicine

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

New Study Challenges Existing Theories about Alzheimer’s Disease

Scientific Review Highlights Stigma Directed at People Living with Chronic Pain

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

MetAlert, Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space

America Faces Shortage of Infectious Disease Experts

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search